Pulmobiotics is a biotech startup based in Barcelona, Spain, that operates in the healthcare sector. It is a spin-off from the Centre for Genomic Regulation and is backed by experienced entrepreneurs. The company's primary focus is on developing innovative live biotherapeutics for the treatment of respiratory diseases, which are among the leading causes of severe illness and death globally.

Pulmobiotics uses a unique and proprietary genetic toolkit to modify the genome of different bacteria. This innovative approach allows the company to create new treatments for a variety of lung diseases, including Chronic Obstructive Pulmonary Disease (COPD), lower respiratory infections, and cancers of the trachea, bronchus, and lung.

The company's business model revolves around the development and commercialization of these novel biotherapeutics. It generates revenue by creating effective treatments for respiratory diseases and selling them to healthcare providers. Its target market includes patients suffering from respiratory diseases, healthcare providers, and medical institutions worldwide.

Pulmobiotics also aims to revolutionize the delivery system of these treatments, providing more effective solutions for various lung diseases. This innovative approach could potentially improve the quality of life for millions of patients worldwide and reduce the global death rate from respiratory diseases.

Keywords: Biotech, Healthcare, Respiratory Diseases, Biotherapeutics, Genome Editing, Lung Diseases, COPD, Respiratory Infections, Lung Cancer, Treatment Delivery System.